Artigo Revisado por pares

Infliximab Plus Plasma Exchange Rescue Therapy in Kawasaki Disease

2014; Elsevier BV; Volume: 164; Issue: 5 Linguagem: Inglês

10.1016/j.jpeds.2014.01.020

ISSN

1097-6833

Autores

Kaori Sonoda, Masaaki Mori, Tatsunori Hokosaki, Shumpei Yokota,

Tópico(s)

Mechanical Circulatory Support Devices

Resumo

Objective To evaluate infliximab (IFX) in patients with Kawasaki disease (KD) that was unresponsive to additional intravenous immunoglobulin (IVIG) therapy and subsequent rescue with supplementary plasma exchange (PE) in patients unresponsive to treatment. Study design We studied 76 patients with KD who received IVIG therapy twice and were unresponsive to additional IVIG. Reults Seventy were treated with IFX alone (92.1%). Six patients who were unresponsive IFX (7.9%) were further treated by PE. This resulted in disappearance of fever and other clinical symptoms, and improvement of laboratory data. There was no severe life-threatening adverse events.Twelve of the 76 cases had developed coronary artery dilatation, and 3 had coronary artery aneurysm within 1 month of disease onset. At the end of follow-up, in all cases, coronary artery lesions were suppressed or reversed. Conclusions Treatment of intractable KD with sequential IVIG, IFX, and PE treatments in a step-wise protocol was effective. To evaluate infliximab (IFX) in patients with Kawasaki disease (KD) that was unresponsive to additional intravenous immunoglobulin (IVIG) therapy and subsequent rescue with supplementary plasma exchange (PE) in patients unresponsive to treatment. We studied 76 patients with KD who received IVIG therapy twice and were unresponsive to additional IVIG. Seventy were treated with IFX alone (92.1%). Six patients who were unresponsive IFX (7.9%) were further treated by PE. This resulted in disappearance of fever and other clinical symptoms, and improvement of laboratory data. There was no severe life-threatening adverse events.Twelve of the 76 cases had developed coronary artery dilatation, and 3 had coronary artery aneurysm within 1 month of disease onset. At the end of follow-up, in all cases, coronary artery lesions were suppressed or reversed. Treatment of intractable KD with sequential IVIG, IFX, and PE treatments in a step-wise protocol was effective.

Referência(s)